semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 0.0-5.0,  Latent Tuberculosis for initial evaluation (clinical and paraclinical) Child under five years of age Household contact of smear positive confirmed pulmonary tuberculosis patient That the parents or legal guardian sign the informed consent To live in Medellín or the Metropolitan Area of the Aburrá Valley. Diagnostic for latent tuberculosis Asymptomatic child Normal clinical assessment, without clinical signs of active TB Normal chest x-ray Response to the tuberculin skin test (TST) ≥5 mm and / IGRA (QuantiFERON®-TB Gold Plus QFT Plus) positive. to start treatment for latent tuberculosis infection  for receiving treatment for latent tuberculosis Having symptoms or signs of active TB and that the disease has not been ruled out Having basic liver disorder for performing induced sputum • Having severe asthma
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COVID Corona Virus Infection Outpatients ≥ 18 years presenting to Cleveland Clinic Health System in Ohio and Florida who test positive for COVID-19 having any of the following symptoms 1. Fever or chills 2. Shortness of breath or difficulty breathing 3. Cough 4. Fatigue 5. Muscle or body Aches 6. Headache 7. New loss of taste 8. New loss of smell 9. Congestion or runny nose 10. Nausea 11. Vomiting 12. Diarrhea Women of child bearing potential: 1. have had a menstrual period within the past 30 days, or 2. have had previous sterilization, or 3. are perimenopausal (less than 1 year) who have a negative pregnancy test, or 4. women of childbearing potential who do not meet the above and have a negative pregnancy test  Patients who are found to be positive during hospitalization Patients who reside outside Ohio or Florida Pregnant women: 1. Current known pregnancy 2. Positive pregnancy test (women of child bearing potential who have not had previous sterilization as defined as hysterectomy or tubal ligation) Women of childbearing potential who do not meet the above last menstrual period greater than 30 days and have a positive pregnancy test Lactating Women End stage kidney disease Advanced liver disease awaiting transplant History of Calcium Oxalate kidney stones
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 16.0-70.0,  Mycobacterium Pulmonary Infection Suspected cases of mycobacterial lung infection  No sputum Refused or unable to tolerate bronchoscopy
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COVID-19 Patients presenting with COVID-19 related symptoms including: fever, persistent cough, fatigue, shortness of breath, diarrhoea, abdominal pain, chest pain, sore throat, loss of smell or taste Subjects in prolonged contact with COVID-19 infected patients  Patients directly admitted to the intensive care unit were excluded Patients opposing use of their health data
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  COVID 19 Age 18-80 years Symptomatic CoVID-19 disease requiring hospitalization SARS-CoV-19 PCR positive Elevated hsTPN  Multi-organ / system failure Renal insufficiency (eGFR <30 or renal replacement therapy) Liver dysfunction (>3x ULN SGOT / SGPT) Chronic Immunosuppression therapy Prior organ transplant Prior multiple transfusions for Myelodysplastic syndrome Prior treatment with plasma, immunoglobulin transfusion within 30 days Allergic reaction to blood/ plasma products Pregnant or breast feeding at the time of study Inability to provide informed consent
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Coronavirus Infection Acute Respiratory Distress Syndrome COVID Age 18 or older 2. Positive revere transcription polymerase chain reaction (RT-PCR) for COVID-19 in a respiratory track sample 3. Acute (less than 36 hours) onset of moderate to severe ARDS, as defined by Berlin Having pneumonia or worsening respiratory symptoms Bilateral pulmonary infiltrates on chest imaging (X-ray of CT scan) Pulmonary wedge pressure <18 mmHg or no clinical signs of left heart failure Hypoxemia: arterial oxygen pressure/Fraction of inspired oxygen (PaO2/FiO2 ratio) <200mmHg, moderate dyspnea with signs of important respiratory workload, tachypnoea >30bpm 4. Rise of inflammatory biomarkers: C-reactive protein (CRP) >10 mg/L  Patients with a known contraindication for anticoagulation 2. Pregnancy or breast feeding 3. Patient already included in another research study 4. Decision by a physician that involvement in the study is not in the patient's best interest 5. Failure to have patient's authorization. In case of a mechanical intubated patient, lack of authorization from a first line family member 6. Multi-organ failure 7. Patients treated with Tocilizumab at the time of start filtration
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Covid-19 (New Coronavirus) Infection Hospitalized at the Kantonsspital Winterthur (KSW) due to COVID-19 infection (laboratory-confirmed) with or without mechanically assisted ventilation being at risk to obtain severe illness caused by the COVID-19* individuals without defined risk factors but requiring oxygenation during hospitalisation Agree to general consent or specific consent to subsequent use of his/her personal health data for research purpose German-speaking  Presence of mental disability or impairments to reasoning or judgment Individuals who are immunocompromised due to medical treatment A documented objection of subsequent use of personal health data Specific for presence at the hospital (for evaluation and training); will be verified during the phone-based screening process. After two weeks of a COVID-19 positive diagnosis and with four entire days the patient reports no signs of fever >37.3° C sore throat cough (productive or non-productive) common cold Also, treatment-based immunocompromised patients are excluded for on-site evaluation and training
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  COVID-19 Age ≥ 50 years Patients with confirmed diagnosis of SARS-Cov2 infection by RT-PCR on nasopharyngeal swab and / or bronchoalveolar lavage (BAL) Patient with Brescia Covid Respiratory Severity Scale (BCRSS) score 2-3 Suggestive picture finding for interstitial pneumonia on chest X-ray and / or chest CT (optional) At least 3 of the following laboratory PCR> 5 times the maximum limit of the normal value Ferritin> 500 ng / ml lactate dehydrogenase (LDH) > 2 times the maximum limit of the normal value D-dimer> 3 times the maximum limit of the normal value Aspartate aminotransferase (AST)> 2 times the maximum limit of the normal value  Age <50 years Brescia Covid Respiratory Severity Scale (BCRSS) score greater than 3 Patients undergoing invasive mechanical ventilation Patients with active autoimmune systemic diseases Patients with active infections that are not responsive to current treatment Patients with a positive pregnancy test Impossibility to maintain the set-up necessary for radiotherapy treatment Other concomitant treatments for COVID-19 do not represent an criterion, however they must be reported (specifying the starting date and dosage)
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Upper Respiratory Tract Infections Virus COVID Virus Shedding Virus Diseases Adults (≥18 years) Those living within the UK Those self-isolating at home within 48 hours of the start of the illness with: 1. Clinical symptoms suggestive of COVID-19 (i.e. those who have at least one of the following symptoms: recent onset of (i) new continuous cough and/or (ii) high temperature) and/or (iii) loss of, or change in, sense of smell or taste (anosmia) OR 2. Those with virologically confirmed SARS-CoV-2 infection and clinical symptoms indicative of COVID-19 (as detailed in (a) above) Provision of informed consent  Onset of illness>48 hours Inability to consent Pregnancy Immunosuppression Inability to perform HSNIG Those taking part in another interventional medical trial Those without access to a supply of salt Those who have had a negative COVID-19 swab result for the present symptoms Those with suspected/confirmed COVID-19 in whom hospital admission is recommended Those who do not have access to email/internet
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Heart Failure Diabetic patient type 2 with history of chronic heart failure(HFrEF) ,there is no prespecified criterion with respect to heart failure etiology and/or ejection fraction  Other etiologies of fluid overload different from heart failure. 2. Hyponatremia: Sodium level below 125mmol/l 3. Unstable patients: acute coronary syndrome, cardiogenic shock . 4. Patients requiring inotropic agents or renal dialysis. 5. Pregnancy or breastfeeding period. 6. sever hepatic disease 7. GFR is less than 45 mL/min/1.73 m² . 8. Patient with diabetic ketoacidosis or non ketotic hyperosmolar
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Covid-19 SARS-CoV 2 SARS Pneumonia Any gender Age > 18 years on day of signing informed consent Informed written consent for participation in the study Virological diagnosis of SARS-CoV-2 infection (real-time PCR) Hospitalized due to clinical instrumental diagnosis of pneumonia Oxygen saturation at rest in ambient air ≤93% or P/F ratio <250 Able to be administered by oral route drugs Patients who receive O2 therapy or who need non-invasive mechanical ventilation In case of female patients at childbearing potential, they should agree to use highly effective methods of birth control at least till 7 days after the termination of the treatments  Known hypersensitivity to Baricitinib or its excipients Patients with Creatinine Clearance < 30 ml/min Patients with active Tuberculosis (TBC) Patients with known HBV or HCV infection Patients with deep vein thrombosis (DVP) or Pulmonary Embolism (PE) Patients with ALT or AST> 5 times the upper limit of the normality Neutrophils <1000/mmc Platelets <50.000/mmc Hb< 8g/dl Bowel diverticulitis or perforation
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Delirium Confusion Mental Status Change Back Pain Hip Pain Chronic Chest Pain Asthma COPD Cellulitis Soft Tissue Infections Cough Deep Vein Thrombosis Pulmonary Embolism Venous Thromboembolism Dyspnea Electrolyte Metabolism Abnormal Fever Failure to Thrive Weakness Protein-Calorie Malnutrition Headache Neck Pain Hypoxia Pneumonia Sepsis Syncope Vomiting Diarrhea Leg Pain Abdominal Pain Age 18 or older Adult patients admitted to General Medicine Services at Brigham and Women's Hospital during the 21-months study data collection period English speakers Patients who were diagnosed with any of the following conditions and symptoms upon admission Abdominal pain Altered mental status/ delirium / confusion Asthma / chronic obstructive pulmonary disease (COPD) Cellulitis / soft tissue infection Chest pain Cough  Not pregnant women, prisoners and institutionalized individuals